Activin A enhances MMP-7 activity via the transcription factor AP-1 in an esophageal squamous cell carcinoma cell line

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 453-459

  Yoshinaga, Keiji ^a   Mimori, Koshi ^a   Inoue, Hiroshi ^a   Kamohara, Yukio ^a   Yamashita, Keishi ^a   Tanaka, Fumiaki ^a   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Activin A; AP 1; Esophageal carcinoma; MMP 7

Indexed keywords

ACTIVIN A; MATRILYSIN; NEUTRALIZING ANTIBODY; PROTEIN C JUN; PROTEIN SUBUNIT; SMAD PROTEIN; TRANSCRIPTION FACTOR AP 1; INHIBIN; INHIBIN BETA A SUBUNIT; MESSENGER RNA;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; IMMUNOBLOTTING; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; INHIBIN-BETA SUBUNITS; MATRIX METALLOPROTEINASE 7; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 54849187300     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000027     Document Type: Article

References (31)

1. Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H and Mori M: Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 22: 75-80, 2003.
2. Kleeff J, Ishiwata T, Friess H, Buchler MW and Korc M: Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 77: 860-868, 1998.
3. Thomas TZ, Wang H, Niclasen P, et al: Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 82: 3851-3858, 1997.
4. Zheng W, Luo MP, Welt C, et al: Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69: 23-31, 1998.
5. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW and Korc M: Overexpression of activin A in stage IV colorectal cancer. Gut 49: 409-417, 2001.
6. Petraglia F, Florio P, Luisi S, et al: Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 83: 1194-1200, 1998.
7. Kojima I and Ogata E: Dual effect of activin A on cell growth in Balb/c 3T3 cells. Biochem Biophys Res Commun 159: 1107-1113, 1989.
8. Rabinovici J, Spencer S and Jaffe S: Recombinant human activin-A promotes proliferation of human luteinized preovulatory granulosa cells in vitro. J Clin Endocrinol Metab 71: 1396-1398, 1990.
9. Di Simone N, Crowley WF Jr, Wang QF, Sluss PM and Schneyer AL: Characterization of inhibin/activin subunit, follistatin and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137: 486-494, 1996.
10. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A and Matzuk MM: Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 10: 534-543, 1996.
11. Matrisian LM: The matrix-degrading metalloproteinases. BioEssays 14: 455-463, 1992.
12. Imai K, Yokohama Y, Nakanishi I, et al: Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymatic properties. J Biol Chem 270: 6691-6697, 1995.
13. Murphy G, Cocket M, Ward R and Docherty AJP: Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: a quantitative comparison of the activities of 95 and 72 kDa gelatinases, stromelysin-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277: 277-279, 1991.
14. Sires UI, Griffin GL, Broekelmann TJ, et al: Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem 268: 2069-2074, 1993.
15. Crabbe T, Smith B, O'Connell J and Docherty A: Human progelatinase A can be activated by matrilysin. FEBS Lett 345: 14-16, 1994.
16. Sang QA, Bodden MK and Windsor LJ: Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin. J Protein Chem 15: 243-253, 1996.
17. Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG and Senior RM: Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alantitrypsin. Biochem Biophys Res Commun 204: 613-620, 1994.
18. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T and Sugimachi K: Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 75: 1516-1519, 1995.
19. Honda M, Mori M, Ueo H, Sugimachi K and Akiyoshi T: Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 39: 444-448, 1996.
20. Yamashita K, Mori M, Shiraishi T, Shibata K and Sugimachi K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6: 1169-1174, 2000.
21. Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH and Matrisian LM: Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 269: 2032-2040, 1994.
22. Mori M, Shiraishi T, Tanaka S, et al: Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Br J Cancer 79: 211-213, 1999.
23. Mori M, Mimori K, Inoue H, et al: Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 55: 3417-3420, 1995.
24. Sugimachi K, Matsuura H, Kai H, et al: Prognostic factors of esophageal carcinoma: univariate and multivariate analyses. J Surg Oncol 31: 108-112, 1986.
25. Yoshinaga K, Inoue H, Utsunomiya T, et al: N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin Cancer Res 10: 5702-5707, 2004.
26. Crawford H, Fingleton B, Gustavson M, et al: The PEA3 sub-family of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 21: 1370-1383, 2001.
27. Tardif G, Reboul P, Dupuis M, et al: Transforming growth factor-beta induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and PEA-3 binding sites. J Rheumatol 28: 1631-1639, 2001.
28. Norwitz ER, Xu S, Xu J, et al: Direct binding of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene. J Biol Chem 277: 37469-37478, 2002.
29. Le Floch N, Rivat C, De Wever O, et al: The proinvasive activity of Wnt-2 is mediated through a non-canonical Wnt pathway coupled to GSK-3beta and c-Jun/AP-1 signaling. FASEB J 19: 144-146, 2005.
30. Rivat C, Le Floch N, Sabbah M, et al: Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J: 1721-1723, 2003.
31. Pacheco MM, Kowalski LP, Nishimoto IN and Brentani MM: Differential expression of c-Jun and c-Fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B and matrilysin mRNAs. Head Neck 24: 24-32, 2002.